卡培他滨联合紫杉醇治疗晚期转移性鼻咽癌37例

Sixty Patients of Metastatic Breast Cancer Resistent to Anthracyclins Treated With Docetaxel Plus Xeloda

目的探讨卡培他滨(希罗达)联合紫杉醇治疗晚期转移性鼻咽癌的疗效及不良反应。方法联合组37例确诊蒽环类耐药的转移性乳腺癌,口服希罗达每日1650mg/(m2·d),连服1-14天,紫杉醇80mg/m2静脉滴注,第1天应用,每3周为1周期,连用2-4周期;对照组31例DDP20mg/m2静脉注射,第1-5天,5-Fu0.5mg/m2第1-5天,3周为1周期,连用2-4周期;治疗结束2周后评价疗效。结果联合组疗效可评价35例,有效率(CR+PR)45.7%(16例),中位生存时间>14.3月;安全性方面Ⅲ反应占25.7%(9例),Ⅳ反应占20.0%(7例),主要为手足综合征、骨髓抑制和消化道毒性。对照组疗效可评价29例,有效率(CR+PR)31.0%(9例),中位生存时间>10.9月,安全性方面Ⅲ反应占34.4%(10例),Ⅳ反应占17.2%(5例),主要为脱发、消化道毒性、骨髓抑制。结论希罗达联合紫杉醇对晚期转移性鼻咽癌的疗效较DDP+5-Fu有优势,且不良反应可以耐受。

Objective To study the efficacy and adverse effect of patients of metastatic breast cancer resistent to anthracyclins treated with docetaxel plus xeloda.Methods Sixty-one patients of metastatic breast cancer resistent to anthracyclins were randomized into two groups:31 in the experimental group and thirty in the control group.The experimental group:Xeloda 1650mg/(m^2·d), d1-d 14 ,Docetaxel 75mg/m^2,intravenous infusion, d1. The control group: Docetaxel 75mg/m^2,intravenous infusion, d1.The two regimens were repeated every three weeks and totally four cycles.The evaluation is performed two weeks after the completion of chemotherapy.Results Sixty-one patients all had evaluable lesions.For the experimental group:the RR rate is 45.2%,median survival is 14.3 months.Grade II-III toxicity 67.7%,Grade IV 29%,are mainly hand-foot syndrome,myelosuppression,alopecia and GI discomfort.For the control group: the RR rate is 30.0%,median survival is 10.9months. Grade II-III toxicity 50%,Grade IV 33.3%,are mainly fever,myalgia,anthralgia and neutropenia.Conclusion Docetaxel with xeloda is effective to patients of metastatic breast cancer resistent to anthracyclins and the toxicity is tolerability.